220 related articles for article (PubMed ID: 27256139)
1. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of hERG potassium channel inhibition by disopyramide.
El Harchi A; Zhang YH; Hussein L; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2012 Jan; 52(1):185-95. PubMed ID: 21989164
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.
Melgari D; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2015 Sep; 86():42-53. PubMed ID: 26159617
[TBL] [Abstract][Full Text] [Related]
5. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
6. Structural implications of hERG K
Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE
J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant.
Al-Moubarak E; Shiels HA; Zhang Y; Du C; Hanington O; Harmer SC; Dempsey CE; Hancox JC
Cell Mol Life Sci; 2021 Dec; 78(23):7899-7914. PubMed ID: 34727194
[TBL] [Abstract][Full Text] [Related]
8. Serine mutation of a conserved threonine in the hERG K
Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
[TBL] [Abstract][Full Text] [Related]
9. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
10. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
11. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
Melgari D; Brack KE; Zhang C; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25911606
[TBL] [Abstract][Full Text] [Related]
12. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
13. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
Du C; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y; Iwata M; Kamiya N; Yamada M; Kinoshita K; Fukunishi Y; Tsujimae K; Hibino H; Aizawa Y; Inanobe A; Nakamura H; Kurachi Y
Channels (Austin); 2007; 1(3):198-208. PubMed ID: 18690032
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue.
Helliwell MV; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765012
[No Abstract] [Full Text] [Related]
16. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
Kiehn J; Thomas D; Karle CA; Schöls W; Kübler W
Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):212-9. PubMed ID: 10208308
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
Zhang P; Xing J; Luo A; Feng J; Liu Z; Gao C; Ma J
J Pharm Pharmacol; 2013 Sep; 65(9):1321-8. PubMed ID: 23927470
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
20. Effect of sibutramine HCl on cardiac hERG K+ channel.
Kim KS; Kim EJ; Lee HA; Park SJ
Mol Cell Biochem; 2009 Jan; 320(1-2):125-31. PubMed ID: 18781376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
